New Drug Repositioning Candidates for T-ALL Identified Via Human/Murine Gene Signature Comparison

T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive subtype of leukemia for which important progress in treatment efficiency have been made in the past decades to reach a cure rate of 75%–80% nowadays. It is nevertheless mandatory to find new targets and active molecules for innovative ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnet, Raphaël, Nebout, Marielle, Brousse, Carine, Reinier, Frédéric, Imbert, Véronique, Rohrlich, Pierre Simon, Peyron, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680901/
https://www.ncbi.nlm.nih.gov/pubmed/33240808
http://dx.doi.org/10.3389/fonc.2020.557643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680901/
https://www.ncbi.nlm.nih.gov/pubmed/33240808
http://dx.doi.org/10.3389/fonc.2020.557643

Ejemplares similares